Analysts predict that Nextgen Healthcare Inc (NASDAQ:NXGN) will post $123.57 million in sales for the current quarter, Zacks reports. Eight analysts have issued estimates for Nextgen Healthcare’s earnings, with estimates ranging from $115.21 million to $134.76 million. Nextgen Healthcare posted sales of $134.26 million during the same quarter last year, which suggests a negative year over year growth rate of 8%. The company is expected to report its next earnings results on Wednesday, October 28th.
According to Zacks, analysts expect that Nextgen Healthcare will report full-year sales of $518.53 million for the current year, with estimates ranging from $479.70 million to $565.00 million. For the next financial year, analysts expect that the firm will post sales of $555.40 million, with estimates ranging from $525.87 million to $595.30 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Nextgen Healthcare.
Nextgen Healthcare (NASDAQ:NXGN) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.17. The business had revenue of $130.88 million for the quarter, compared to analysts’ expectations of $115.11 million. Nextgen Healthcare had a net margin of 1.01% and a return on equity of 10.64%.
A number of research analysts recently issued reports on NXGN shares. Cantor Fitzgerald lifted their price objective on shares of Nextgen Healthcare from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Friday. Royal Bank of Canada started coverage on shares of Nextgen Healthcare in a research note on Monday, April 20th. They issued a “sector perform” rating and a $11.00 price objective on the stock. SVB Leerink started coverage on shares of Nextgen Healthcare in a research note on Monday, April 13th. They issued a “market perform” rating and a $12.00 price objective on the stock. Deutsche Bank decreased their price objective on shares of Nextgen Healthcare from $12.00 to $9.00 and set a “hold” rating on the stock in a research note on Tuesday, June 2nd. Finally, Robert W. Baird decreased their target price on shares of Nextgen Healthcare from $16.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, May 7th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $12.46.
Shares of NASDAQ:NXGN opened at $14.62 on Thursday. The company’s 50 day simple moving average is $10.96 and its 200 day simple moving average is $11.42. The stock has a market capitalization of $975.30 million, a price-to-earnings ratio of 162.44, a price-to-earnings-growth ratio of 5.02 and a beta of 0.99. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.82 and a quick ratio of 1.82. Nextgen Healthcare has a 1 year low of $5.10 and a 1 year high of $18.49.
Several large investors have recently modified their holdings of the company. Comerica Bank lifted its holdings in shares of Nextgen Healthcare by 9.0% during the second quarter. Comerica Bank now owns 62,447 shares of the company’s stock worth $722,000 after purchasing an additional 5,145 shares during the period. Pacer Advisors Inc. lifted its holdings in shares of Nextgen Healthcare by 44.3% during the second quarter. Pacer Advisors Inc. now owns 10,810 shares of the company’s stock worth $119,000 after purchasing an additional 3,320 shares during the period. Strs Ohio lifted its holdings in shares of Nextgen Healthcare by 11.5% during the second quarter. Strs Ohio now owns 53,400 shares of the company’s stock worth $586,000 after purchasing an additional 5,500 shares during the period. Stone Ridge Asset Management LLC lifted its holdings in shares of Nextgen Healthcare by 20.5% during the second quarter. Stone Ridge Asset Management LLC now owns 22,963 shares of the company’s stock worth $252,000 after purchasing an additional 3,900 shares during the period. Finally, Smith Graham & Co. Investment Advisors LP lifted its holdings in shares of Nextgen Healthcare by 39.1% during the second quarter. Smith Graham & Co. Investment Advisors LP now owns 930,706 shares of the company’s stock worth $10,219,000 after purchasing an additional 261,429 shares during the period. Institutional investors own 73.22% of the company’s stock.
Nextgen Healthcare Company Profile
NextGen Healthcare, Inc provides software, services, and analytics solutions to medical and dental group practices in the United States. The company's principal products include NextGen Enterprise EHR, which stores and maintains clinical patient information; and a workflow module, prescription management, automatic document and letter generation, patient education, referral tracking, interfaces to billing and lab systems, physician alerts and reminders, and reporting and data analysis tools.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nextgen Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nextgen Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.